Rights and permissions
About this article
Cite this article
Adjuvant imatinib worth the cost in GIST patients. Pharmacoecon. Outcomes News 617, 10 (2010). https://doi.org/10.2165/00151234-201006170-00014
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201006170-00014